著者
Cabral Horacio 垣見 和宏 内田 智士
出版者
東京大学
雑誌
基盤研究(B)
巻号頁・発行日
2020-04-01

We will first develop a series of T-cell targeted mRNA-loaded nanocarriers. These nanocarriers will be optimized for stability, targeting and protein production in vitro.Promising formulations will then be tested in vivo. to determine the targeting efficacy to the CD8 T cells, the production of CAR T cell in situ and the antitumor activity against models of leukemia and solid tumors. Finally, we will check the toxicity of the treatments.

言及状況

Twitter (1 users, 1 posts, 0 favorites)

ナノキャリアは東大発ベンチャー企業、今後mRNAに特化

収集済み URL リスト